This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Filep, J. G. Articles by Szegedi, G. Search for Related Content PubMed PubMed Citation Articles by Filep, J. G. Articles by Szegedi, G. Pubmed/NCBI databases Substance via MeSH

(Circulation. 1995;92:2969-2974.)
© 1995 American Heart Association, Inc.

Articles

Plasma Endothelin Correlates With Antiendothelial Antibodies in Patients With Mixed Connective Tissue Disease

János G. Filep, MD; Edit Bodolay, MD; Sándor Sipka, MD; Edit Gyimesi, PhD; István Csipö, PhD; Gyula Szegedi, MD, DMSc

From the Research Center (J.G.F.), Maisonneuve-Rosemont Hospital, Department of Medicine, University of Montréal, Montréal, Quebec, Canada; and Third Department of Medicine (E.B., S.S., E.G., I.C., G.S.), Debrecen University Medical School, Debrecen, Hungary.

Correspondence to János G. Filep, MD, Research Center, Maisonneuve-Rosemont Hospital, University of Montréal, 5415 Boulevard de l'Assomption, Montréal, Quebec, Canada H1T 2M4.

Background Elevated circulating levels of the vasoactive peptide endothelin-1 have been reported in various cardiovascular disorders. Because these conditions are frequently associated with endothelial dysfunction and damage and the vasoconstrictor effect of endothelin-1 is believed to be produced at the local vascular level, it is uncertain whether circulating endothelin-1 is a causal factor in enhanced vascular tone or instead a marker of endothelial injury.

Methods and Results We tested whether elevated immunoreactive endothelin-1 could be detected by radioimmunoassay in plasma and whether endothelin-1 levels correlated with antiendothelial autoantibodies in patients with mixed connective tissue disease. Venous blood samples were collected from 21 patients in the morning after an overnight fast and before medication. The plasma immunoreactive endothelin-1 level was 2.7±0.5 pg/mL (range, 1.1 to 5.2 pg/ml; n=9) and 7.3±1.5 pg/mL (range, 2.8 to 20.7 pg/mL; n=12) in patients who had no antiendothelial antibodies and in patients with antiendothelial antibodies, respectively. These latter values were significantly (P<.001) increased compared with 10 age-matched healthy volunteers (2.0±0.3 pg/mL; range, 0.5 to 3.0 pg/mL). Plasma endothelin-1 level strongly correlated with antiendothelial antibodies (r_s=.836, n=21, P<.001), whereas there was no correlation between age, systolic and diastolic blood pressures, antinuclear antibodies, and duration of the disease and endothelin-1 values. The incidence of Raynaud's phenomenon and angina did not differ significantly in patients with low and high endothelin-1 levels.

Conclusions This study showed that mixed connective tissue disease is associated with elevated plasma immunoreactive endothelin-1 and that endothelin-1 levels significantly correlate with antiendothelial autoantibodies. These findings suggest that increases in plasma endothelin-1 concentration may be secondary to vascular injury and do not necessarily represent enhanced susceptibility to vasoconstriction.

Key Words: endothelin • antibodies • endothelium

This article has been cited by other articles:

				S Hennigan, R. Channick, and G. Silverman Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report Lupus, August 1, 2008; 17(8): 754 - 756. [Abstract] [PDF]

				N Galie, A Manes, K V Farahani, F Pelino, M Palazzini, L Negro, S Romanazzi, and A Branzi Pulmonary arterial hypertension associated to connective tissue diseases Lupus, September 1, 2005; 14(9): 713 - 717. [Abstract] [PDF]

				J. J Jang, J. W Olin, and V. Fuster A teenager with mixed connective tissue disease presenting with an acute coronary syndrome Vascular Medicine, February 1, 2004; 9(1): 31 - 34. [Abstract] [PDF]

				N. Galie, A. Manes, and A. Branzi The endothelin system in pulmonary arterial hypertension Cardiovasc Res, February 1, 2004; 61(2): 227 - 237. [Abstract] [Full Text] [PDF]

				D. Henrion, M. Iglarz, and B. I. Levy Chronic Endothelin-1 Improves Nitric Oxide–Dependent Flow-Induced Dilation in Resistance Arteries From Normotensive and Hypertensive Rats Arterioscler Thromb Vasc Biol, September 1, 1999; 19(9): 2148 - 2153. [Abstract] [Full Text] [PDF]

				J. Frostegard, R. Wu, C. Gillis-Haegerstrand, C. Lemne, and U. de Faire Antibodies to Endothelial Cells in Borderline Hypertension Circulation, September 15, 1998; 98(11): 1092 - 1098. [Abstract] [Full Text] [PDF]

				J. G. Filep Endogenous Endothelin Modulates Blood Pressure, Plasma Volume, and Albumin Escape After Systemic Nitric Oxide Blockade Hypertension, July 1, 1997; 30(1): 22 - 28. [Abstract] [Full Text]